Filing Flows › Nephros (NEPH) › R&D spending
Nephros (NEPH) R&D spending by quarter
Nephros' R&D spending was $331K in Q3 2026 (third quarter 2026), -10% from Q2 2026. Over the last 7 quarters it ranged from $295K (Q1 2025) to $395K (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $331K | -10% | -2% |
| Q2 2026 | $366K | +6% | +18% |
| Q1 2026 | $346K | -12% | +17% |
| Q4 2025 | $395K | +17% | — |
| Q3 2025 | $338K | +9% | — |
| Q2 2025 | $311K | +5% | — |
| Q1 2025 | $295K | — | — |
Q3 2026 at a glance
Nephros, Q3 2026: revenue $5.6M (+18% year over year), operating margin 8.9%, net earnings $512K, operating cash flow −$150K. The chart follows the revenue to costs, profit and cash.
Questions
What is Nephros' R&D spending?
Nephros' R&D spending was $331K in Q3 2026 (third quarter 2026), -10% from Q2 2026.
How has Nephros' R&D spending changed?
Over the last 7 quarters it ranged from $295K (Q1 2025) to $395K (Q4 2025).